Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | PLAU | P00749 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7969673 | 0.89 | KMT2A (0.51) | ALDH1A1LMNAGAAL3MBTL1MEN1 | |
| SCHEMBL6078213 | 0.83 | ALDH1A1 (0.59) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6079143 | 0.83 | ALDH1A1 (0.64) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6078277 | 0.82 | LMNA (0.67) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6079643 | 0.81 | ALDH1A1 (0.65) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6078839 | 0.81 | LMNA (0.55) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6078668 | 0.81 | LMNA (0.55) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6078676 | 0.81 | LMNA (0.64) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6077582 | 0.79 | ALDH1A1 (0.52) | ALDH1A1LMNAGAAL3MBTL1MAPT | |
| SCHEMBL6429403 | 0.79 | LMNA (0.62) | ALDH1A1LMNAGAAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1181271-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | Telik, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000071506-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | ALDH1A1 3426/4885LMNA 3288/4885GAA 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.